1、For immediate release Johnson&Johnson reports Q3 2025 results;raises 2025 sales outlook 2025 Third-Quarter reported sales growth of 6.8%to$24.0 Billion with operational growth of 5.4%*and adjusted operationalgrowth of 4.4%*2025 Third-Quarter reflects earnings per share(EPS)of$2.12 and adjusted E

2、PS of$2.80Significant innovation including approvals of INLEXZO for high-risk non-muscle invasive bladder cancer and TREMFYAsubcutaneous in ulcerative colitis,submission of icotrokinra for plaque psoriasis,landmark data for RYBREVANT plusLAZCLUZE overall survival in non-small cell lung cancer,and Da

3、nGer Shock long-term survival benefit of Impella Heart PumpCompany increases full year estimated reported sales5 guidance to$93.7B or 5.7%at the midpoint;reaffirms full yearadjusted EPS4 guidance of$10.85 at the midpoint,absorbing higher tax costsNew Brunswick,N.J.(October 14,2025)Johnson&Johnso

4、n(NYSE:JNJ)today announced results for third-quarter 2025.“Johnson&Johnson delivered another strong performance in the third quarter fueled by the depth and strength of our portfolio and significant progress across our pipeline,”said Joaquin Duato,Chairman and Chief Executive Officer,Johnson&

5、;Johnson.“With a sharpened focus on the six priority areas of Oncology,Immunology,Neuroscience,Cardiovascular,Surgery and Vision,Johnson&Johnson is in a new era of accelerated growth and innovation,with pioneering treatments that will continue to transform lives.”Overall financial results Q3($in

6、 Millions,except EPS)2025 2024%Change Reported Sales$23,993$22,471 6.8%Net Earnings$5,152$2,694 91.2%EPS(diluted)$2.12$1.11 91.0%Q3Non-GAAP*($in Millions,except EPS)2025 2024%Change Operational Sales1,2 5.4%Adjusted Operational Sales1,3 4.4%Adjusted Net Earnings1,4$6,801$5,876 15.7%Adjusted EPS(dilu